In a report released on June 30, Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma, with a price target of $53.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mani Foroohar has given his Buy rating due to a combination of factors that highlight BridgeBio Pharma’s strategic financial maneuvers and potential for future growth. The recent financing agreement with HealthCare Royalty and Blue Owl Capital allows BridgeBio to receive a substantial upfront payment by monetizing a portion of its royalties from Bayer. This move is seen as a strategic step to enhance cash flow, which is crucial for supporting the company’s upcoming product launches and pivotal trials.
Additionally, over the past year and a half, BridgeBio has been proactive in strengthening its balance sheet through similar financial strategies. These efforts are aimed at ensuring the company has sufficient funds to reach profitability, making the current announcement a logical continuation of this strategy. Despite a slight dip in share prices, the overall outlook remains positive as the company positions itself for future growth opportunities, particularly with its TTR launch and other significant trials on the horizon.
According to TipRanks, Foroohar is an analyst with an average return of -10.8% and a 41.00% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as RegenXBio, Moderna, and Crispr Therapeutics AG.
In another report released on June 30, Wells Fargo also maintained a Buy rating on the stock with a $76.00 price target.